DASH Trial: Testing Ceralasertib and Trastuzumab Deruxtecan
Phase 1
51
about 4.6 years
18+
23 sites in CA, FL, IL +8
About this study
Researchers are testing a treatment with ceralasertib (AZD6738) and trastuzumab deruxtecan in people with advanced solid tumors that have HER2 changes or protein. The goal is to find the best dose of this combination for safety, side effects, and effectiveness. The trial also compares how colorectal and gastroesophageal cancers respond to treatment with ceralasertib and trastuzumab deruxtecan versus trastuzumab deruxtecan alone.
Based on ClinicalTrials.gov records.
What participants do
- 1.Receive Trastuzumab Deruxtecan
- 2.Take Ceralasertib
- 3.Undergo Biopsy Procedure
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
trastuzumab deruxtecan
infusion
Primary: Differential pharmacodynamic (PD) profile of tumor tissue (DNA damage & repair) (Dose expansion phase), Incidence of adverse events (Dose escalation phase)
Secondary: Best overall response, Disease control rate, Duration of response, Immunogenicity, Objective response rate (ORR), Overall survival, PD markers, Pharmacokinetics
biopsy, diagnostic, imaging
Oncology